Nrf2 knockdown attenuates the ameliorative effects of ligustrazine on hepatic fibrosis by targeting hepatic stellate cell transdifferentiation

Toxicology

Volumn 365, Issue , 2016, Pages 35-47

  Lu, Chunfeng ^a   Xu, Wenxuan ^a   Zhang, Feng ^a   Shao, Jiangjuan ^a   Zheng, Shizhong ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Hepatic fibrosis; Hepatic stellate cell; Ligustrazine; Nuclear factor (erythroid derived 2) like 2; catenin

Indexed keywords

BETA CATENIN; CARBON TETRACHLORIDE; GAMMA INTERFERON; INTERLEUKIN 6; IWR 1ENDO; PROTEIN INHIBITOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TETRAMETHYLPYRAZINE; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL SEPARATION; CELL TRANSDIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOARCHITECTURE; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STELLATE CELL; TARGET CELL; ANIMAL; CELL LINE; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; GENE THERAPY; GENETICS; HEPATIC STELLATE CELL; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; LIVER CIRRHOSIS; METABOLISM;

ANIMALS; BETA CATENIN; CARBON TETRACHLORIDE; CELL LINE; CELL TRANSDIFFERENTIATION; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HEPATIC STELLATE CELLS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MICE, INBRED ICR; NF-E2-RELATED FACTOR 2; PYRAZINES;

EID: 84982797830     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2016.07.018     Document Type: Article

References (46)

1. Blaser, H., Dostert, C., Mak, T.W., Brenner, D., TNF and ROS crosstalk in inflammation. Trends Cell Biol. 26 (2016), 249–261.
2. Burdick, J.A., Prestwich, G.D., Hyaluronic acid hydrogels for biomedical applications. Adv. Mater. 23 (2011), H41–56.
3. Chen, A., Zhang, L., Xu, J., Tang, J., The antioxidant (−)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression. Biochem. J. 368 (2002), 695–704.
4. Cohen-Naftaly, M., Friedman, S.L., Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther. Adv. Gastroenterol. 4 (2011), 391–417.
5. Delima, R.D., Chua, A.C., Tirnitz-Parker, J.E., Gan, E.K., Croft, K.D., Graham, R.M., Olynyk, J.K., Trinder, D., Disruption of hemochromatosis protein and transferrin receptor 2 causes iron-induced liver injury in mice. Hepatology 56 (2012), 585–593.
6. Friedman, S.L., Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7 (2010), 425–436.
7. Gabr, S.A., Alghadir, A.H., Prediction of fibrosis in hepatitis C patients: assessment using hydroxyproline and oxidative stress biomarkers. Virusdisease 25 (2014), 91–100.
8. Ge, W.S., Wang, Y.J., Wu, J.X., Fan, J.G., Chen, Y.W., Zhu, L., Beta-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/beta-catenin signaling inhibits hepatic stellate cell activation. Mol. Med. Rep. 9 (2014), 2145–2151.
9. Guimaraes, E.L., Stradiot, L., Mannaerts, I., Schroyen, B., van Grunsven, L.A., P311 modulates hepatic stellate cells migration. Liver Int. 35 (2015), 1253–1264.
10. Hocking, D.C., Sottile, J., Langenbach, K.J., Stimulation of integrin-mediated cell contractility by fibronectin polymerization. J. Biol. Chem. 275 (2000), 10673–10682.
11. Ilagan, R., Guthrie, K., Quinlan, S., Rapoport, H.S., Jones, S., Church, A., Basu, J., Ludlow, J., Linear measurement of cell contraction in a capillary collagen gel system. Biotechniques 48 (2010), 153–155.
12. Kharbanda, K.K., Rogers, D.D. 2nd, Wyatt, T.A., Sorrell, M.F., Tuma, D.J., Transforming growth factor-beta induces contraction of activated hepatic stellate cells. J. Hepatol. 41 (2004), 60–66.
13. Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., Evans, S.M., Dillmann, W., Glass, C.K., Brenner, D.A., Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 9448–9453.
14. Koo, Y.C., Pyo, M.C., Nam, M.H., Hong, C.O., Yang, S.Y., Lee, K.W., Chebulic acid prevents hepatic fibrosis induced by advanced glycation end-products in LX-2 cell by modulating Nrf2 translocation via ERK pathway. Toxicol. In Vitro 34 (2016), 8–15.
15. Kumar, H., Kim, I.S., More, S.V., Kim, B.W., Choi, D.K., Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases. Nat. Prod. Rep. 31 (2014), 109–139.
16. Li, J.P., Gao, Y., Chu, S.F., Zhang, Z., Xia, C.Y., Mou, Z., Song, X.Y., He, W.B., Guo, X.F., Chen, N.H., Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl4-induced hepatic fibrosis. Acta Pharmacol. Sin. 35 (2014), 1031–1044.
17. Li, W., Zhu, C., Li, Y., Wu, Q., Gao, R., Mest attenuates CCl4-induced liver fibrosis in rats by inhibiting the Wnt/beta-catenin signaling pathway. Gut Liver 8 (2014), 282–291.
18. Liu, H., Dinkova-Kostova, A.T., Talalay, P., Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 15926–15931.
19. Liu, Y., Ko, J.A., Yanai, R., Kimura, K., Chikama, T., Sagara, T., Nishida, T., Induction by latanoprost of collagen gel contraction mediated by human tenon fibroblasts: role of intracellular signaling molecules. Invest. Ophthalmol. Vis. Sci. 49 (2008), 1429–1436.
20. Liu, M., Grigoryev, D.N., Crow, M.T., Haas, M., Yamamoto, M., Reddy, S.P., Rabb, H., Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int. 76 (2009), 277–285.
21. Liu, Z., van Grunsven, L.A., Van Rossen, E., Schroyen, B., Timmermans, J.P., Geerts, A., Reynaert, H., Blebbistatin inhibits contraction and accelerates migration in mouse hepatic stellate cells. Br. J. Pharmacol. 159 (2010), 304–315.
22. Liu, Y., Zhu, P., Wang, Y., Wei, Z., Tao, L., Zhu, Z., Sheng, X., Wang, S., Ruan, J., Liu, Z., Cao, Y., Shan, Y., Sun, L., Wang, A., Chen, W., Lu, Y., Antimetastatic Therapies of the Polysulfide Diallyl Trisulfide against Triple-Negative Breast Cancer (TNBC) via suppressing MMP2/9 by blocking NF-kappaB and ERK/MAPK signaling pathways. PLoS One, 10, 2015, e0123781.
23. Lu, C., Jiang, Y., Zhang, F., Shao, J., Wu, L., Wu, X., Lian, N., Chen, L., Jin, H., Chen, Q., Lu, Y., Zheng, S., Tetramethylpyrazine prevents ethanol-induced hepatocyte injury via activation of nuclear factor erythroid 2-related factor 2. Life Sci. 141 (2015), 119–127.
24. Lu, C., Xu, W., Zhang, F., Jin, H., Chen, Q., Chen, L., Shao, J., Wu, L., Lu, Y., Zheng, S., Ligustrazine prevents alcohol-induced liver injury by attenuating hepatic steatosis and oxidative stress. Int. Immunopharmacol. 29 (2015), 613–621.
25. Lu, C., Zhang, F., Xu, W., Wu, X., Lian, N., Jin, H., Chen, Q., Chen, L., Shao, J., Wu, L., Lu, Y., Zheng, S., Curcumin attenuates ethanol-induced hepatic steatosis through modulating Nrf2/FXR signaling in hepatocytes. IUBMB Life 67 (2015), 645–658.
26. Lv, P., Zhao, J., Su, W., Liang, X., Zhang, K., An experimental novel study: hyperbaric oxygen treatment on reduction of epidural fibrosis via down-regulation of collagen deposition, IL-6, and TGF-beta1. Eur. J. Orthop. Surg. Traumatol. 25:Suppl. (1) (2015), S53–58.
27. Ma, X., Zhang, J., Liu, S., Huang, Y., Chen, B., Wang, D., Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother. Pharmacol. 69 (2012), 485–494.
28. Manigandan, K., Manimaran, D., Jayaraj, R.L., Elangovan, N., Dhivya, V., Kaphle, A., Taxifolin curbs NF-kappaB-mediated Wnt/beta-catenin signaling via up-regulating Nrf2 pathway in experimental colon carcinogenesis. Biochimie 119 (2015), 103–112.
29. Motohashi, H., O'Connor, T., Katsuoka, F., Engel, J.D., Yamamoto, M., Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 294 (2002), 1–12.
30. Niehrs, C., The complex world of WNT receptor signalling. Nat. Rev. Mol. Cell Biol. 13 (2012), 767–779.
31. O'Connell, M.A., Hayes, J.D., The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem. Soc. Trans. 43 (2015), 687–689.
32. Osawa, Y., Oboki, K., Imamura, J., Kojika, E., Hayashi, Y., Hishima, T., Saibara, T., Shibasaki, F., Kohara, M., Kimura, K., Inhibition of Cyclic Adenosine Monophosphate (cAMP)-response Element-binding Protein (CREB)-binding Protein (CBP)/beta-Catenin Reduces Liver Fibrosis in Mice. EBioMedicine 2 (2015), 1751–1758.
33. Qu, J., Yu, Z., Li, Q., Chen, Y., Xiang, D., Tan, L., Lei, C., Bai, W., Li, H., Shang, Q., Chen, L., Hu, X., Lu, W., Li, Z., Chen, D., Wang, X., Zhang, C., Xiao, G., Qi, X., Chen, J., Zhou, L., Chen, G., Li, Y., Zeng, Z., Rong, G., Dong, Z., Lou, M., Wang, C., Lu, Y., Yang, Y., Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials, 15, 2014, 438.
34. Reuland, D.J., Khademi, S., Castle, C.J., Irwin, D.C., McCord, J.M., Miller, B.F., Hamilton, K.L., Upregulation of phase II enzymes through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress. Free Radic. Biol. Med. 56 (2013), 102–111.
35. Rossi, E., Adams, L.A., Ching, H.L., Bulsara, M., MacQuillan, G.C., Jeffrey, G.P., High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis. Clin. Chem. Lab. Med. 51 (2013), 1107–1114.
36. Starkel, P., Leclercq, I.A., Animal models for the study of hepatic fibrosis. Best Pract. Res. Clin. Gastroenterol. 25 (2011), 319–333.
37. Tomita, K., Teratani, T., Suzuki, T., Shimizu, M., Sato, H., Narimatsu, K., Usui, S., Furuhashi, H., Kimura, A., Nishiyama, K., Maejima, T., Okada, Y., Kurihara, C., Shimamura, K., Ebinuma, H., Saito, H., Yokoyama, H., Watanabe, C., Komoto, S., Nagao, S., Sugiyama, K., Aosasa, S., Hatsuse, K., Yamamoto, J., Hibi, T., Miura, S., Hokari, R., Kanai, T., Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells. J. Hepatol. 61 (2014), 98–106.
38. Tosello-Trampont, A.C., Krueger, P., Narayanan, S., Landes, S.G., Leitinger, N., Hahn, Y.S., NKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice. Hepatology 63 (2016), 799–812.
39. Wu, X., Zhang, F., Xiong, X., Lu, C., Lian, N., Lu, Y., Zheng, S., Tetramethylpyrazine reduces inflammation in liver fibrosis and inhibits inflammatory cytokine expression in hepatic stellate cells by modulating NLRP3 inflammasome pathway. IUBMB Life 67 (2015), 312–321.
40. Wynn, T.A., Ramalingam, T.R., Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18 (2012), 1028–1040.
41. Xu, W., Hellerbrand, C., Kohler, U.A., Bugnon, P., Kan, Y.W., Werner, S., Beyer, T.A., The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis. Lab. Invest. 88 (2008), 1068–1078.
42. Xu, W., Lu, C., Zhang, F., Shao, J., Zheng, S., Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR-S1PR2-dependent mechanism. IUBMB Life 68 (2016), 376–387.
43. Yang, J.J., Tao, H., Hu, W., Liu, L.P., Shi, K.H., Deng, Z.Y., Li, J., MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis. Cell. Signal. 26 (2014), 2381–2389.
44. Yu, F., Lu, Z., Huang, K., Wang, X., Xu, Z., Chen, B., Dong, P., Zheng, J., MicroRNA-17-5p-activated Wnt/beta-catenin pathway contributes to the progression of liver fibrosis. Oncotarget 7 (2016), 81–93.
45. Zhang, F., Kong, D.S., Zhang, Z.L., Lei, N., Zhu, X.J., Zhang, X.P., Chen, L., Lu, Y., Zheng, S.Z., Tetramethylpyrazine induces G0/G1 cell cycle arrest and stimulates mitochondrial-mediated and caspase-dependent apoptosis through modulating ERK/p53 signaling in hepatic stellate cells in vitro. Apoptosis 18 (2013), 135–149.
46. Zhang, F., Ni, C., Kong, D., Zhang, X., Zhu, X., Chen, L., Lu, Y., Zheng, S., Ligustrazine attenuates oxidative stress-induced activation of hepatic stellate cells by interrupting platelet-derived growth factor-beta receptor-mediated ERK and p38 pathways. Toxicol. Appl. Pharmacol. 265 (2012), 51–60.